FluoroPharma Medical Inc. announced that it has been collaborating with Royal Philips for data management in conjunction with its Phase II clinical trials for its lead agent CardioPET (18-F FCPHA). The CardioPET image data was put through a rigorous quality assurance process. For this, FluoroPharma collaborated with Philips and its Advanced Molecular Imaging technology to ensure that uniform standards were carefully applied to data from their advanced imaging systems across clinical sites.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0001 USD | -50.00% | -.--% | -.--% |
2022 | FluoroPharma Medical, Inc. Announces Executive Changes | CI |
2022 | FluoroPharma Medical, Inc. Appoints Frank I Igwealor as CFO | CI |
1st Jan change | Capi. | |
---|---|---|
-.--% | 2.76K | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- FPMI Stock
- News FluoroPharma Medical, Inc.
- FluoroPharma Medical Inc. and Royal Philips Collaborate on Image Management for CardioPET Phase II Clinical Trial